Atea Pharmaceuticals, Inc.

Item 5. Other Information.

Other than as disclosed below, during the three months ended March 31, 2026 , no director or “officer” (as defined in Rule 16a-1(f) under the Exchange Act) of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement”, as each term is defined in Item 408(a) of Regulation S-K.

On March 10, 2026, Janet Hammond, MD, PhD, our Chief Development Officer, adopted a trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) (the “Hammond 10b5-1 Plan”). Between September 1, 2026 and September 1, 2027, the Hammond 10b5-1 Plan provides for the potential exercise of vested stock options and associated sale of up to 305,000 shares of Atea common stock acquired upon the exercise of such stock options. The Hammond 10b5-1 Plan expires on September 1, 2027 or upon the earlier completion of all transactions authorized under the Hammond 10b5-1 Plan.

On March 11, 2026, John Vavricka, our Chief Commercial Officer, adopted a trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) (the “Vavricka 10b5-1 Plan”). Between September 1, 2026 and September 1, 2027, the Vavricka 10b5-1 Plan provides for the potential exercise of vested stock options and associated sale of up to 200,000 shares of Atea common stock acquired upon the exercise of such stock options. The Vavricka 10b5-1 Plan expires on September 1, 2027 or upon the earlier completion of all transactions authorized under the Vavricka 10b5-1 Plan.

On March 12, 2026, Arantxa Horga, MD, our Chief Medical Officer, adopted a trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) (the “Horga 10b5-1 Plan”). Between September 1, 2026 and September 1, 2027, the Horga 10b5-1 Plan provides for the potential exercise of vested stock options and associated sale of up to 52,216 shares of Atea common stock acquired upon the exercise of such stock options and the sale of up to 82,697 shares of Atea common stock. The Horga 10b5-1 Plan expires on September 1, 2027 or upon the earlier completion of all transactions authorized under the Horga 10b5-1 Plan.